<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364169">
  <stage>Registered</stage>
  <submitdate>25/03/2015</submitdate>
  <approvaldate>13/05/2015</approvaldate>
  <actrnumber>ACTRN12615000470594</actrnumber>
  <trial_identification>
    <studytitle>Probiotics use impact on metabolic markers, body composition, gut microbiota and immunity markers in prediabetic adolescents.</studytitle>
    <scientifictitle>Evaluating the impact of probiotics use on metabolism  body composition, gut microbiota and immunity markers in prediabetic patients. - A randomized, blind, placebo-controlled trial.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Prediabetes </healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Normal oral and gastrointestinal development and function</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Autoimmune diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>2 sachets of VSL#3 (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus bulgaricus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, and Streptococcus thermophilus) daily, orally, for 4 months. Adherence will be monitored according to sachet number return. </interventions>
    <comparator>2 sachets of inactive cellulose daily, orally, for 4 months</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary outcome is composite. Blood measurement of
1. HbA1C test 
2. Fasting plasma glucose
3. Oral Glucose Tolerance Test </outcome>
      <timepoint>Baseline and 16 weeks after enrolment.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>- Human body composition as assessed by Bio-impedance device and  bio-impedance spectrometry device.
</outcome>
      <timepoint>Baseline and 16 weeks weeks after enrolment.
</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>- Gut flora, via s16 PCR testing.
</outcome>
      <timepoint>Baseline and 4 months after enrolment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>- ECL-IAA, mIAA, GAD65, ZnT8, IA2 antibodies in whole blood.
</outcome>
      <timepoint>Baseline and 4 months after enrolment.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>This is composite and will be comprised of: serum assays of glucose, insulin, pro-insulin, adiponectin, C-Peptide, leptin, hs-CRP, Interleukin IL-6, Interleukin IL-8, Tumor Necrosis Factor Alpha (TNFa), Plasminogen Activator Inhibitor 1 (PAI-1) concentrations.
</outcome>
      <timepoint>Baseline and after enrolment.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>- Psychometric questionnaires DASS21, PSS-14, STAI-C, Problems and Difficulties Questionnaire.</outcome>
      <timepoint>Baseline and after enrolment.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>- Hb1AC ranging from 5.7% to 6.4% or 
- Fasting plasma glucose concentrations ranging from 100 mg/dl to 125 mg/dl or
- At Oral Glucose Tolerance Test within 2 hours: blood glucose ranging from 140 mg/dl to 199 mg/dl</inclusivecriteria>
    <inclusiveminage>12</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>20</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.	Short-bowel syndrome patients, with concurrent D-lactic acidosis.
2.	Current hospitalization for any reason.
3.	Co-morbid infection of any kind.
4.	Co-morbid hereditary and/or acquired immune system deficiency.
5.	Patients with genetic defects in insulin action, diseases of the exocrine pancreas, gestational diabetes, endocrinopathies (Cushings syndrome, acromegaly, glucagonoma, pheochromocytoma, somatostatinoma, aldestoronoma, hyperthyroidism), drug or chemical- induced diabetes (vacor, pentamidine, nicotinic acid, glucocorticoids, thyroid hormone, diazoxide, b-adrenergic agonists, thiazides, clozapine, protease inhibitors), or Stiffmans syndrome.
6.	Ingestion of antibiotics &lt; 1 month, prior enrolment and/or intake of yogurts and products containing probiotics or any immune-compromising agent, whatsoever.
7.	Diarrhoea, due to the probiotics administration, that lasts more than 3 days and/or causes severe dehydration, independently of its duration.
8.	Current detection of HBsAg, HBcAb presence and/or established diagnosis of hepatic disorders of any nature.
9.	Inability to commit to clinical trial follow-up. 
10.	Atopic dermatitis.
11.	Epilepsy.
12.	Established or possible pregnancy.
13.	Presence of metal prostheses, due to orthopaedic surgery or otherwise or implanted devices such as pacemakers.
14.	Established, chronic life-threatening diseases, such as neoplasias.
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>1. Evaluation according to the inclusion and exclusion criteria.
2. Written informed consent will be given, either from the patients themselves or from their guardians.
3. Allocation to the group according to sealed opaque envelopes.</concealment>
    <sequence>The randomization will be performed via the online randomization site : www.random.org</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Nil</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1>False</masking1>
    <masking2>False</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>30/06/2015</anticipatedstartdate>
    <actualstartdate>1/06/2015</actualstartdate>
    <anticipatedenddate>31/08/2017</anticipatedenddate>
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens, Attiki</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Charikleia Stefanaki</primarysponsorname>
    <primarysponsoraddress>34 VYZANTIOU STR
Athens, Attiki
12242</primarysponsoraddress>
    <primarysponsorcountry>Greece</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Athens University Greece</fundingname>
      <fundingaddress>Alkmanos 18 Str
Unit of Applied Research in Endocrinology and Diabetes, Athens University Medical School, Athens, Greece.
18 Alkmanos Street, Athens 11528, Greece.
Tel: +30 6937036030.
</fundingaddress>
      <fundingcountry>Greece</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>1st Department of Pediatrics,

</sponsorname>
      <sponsoraddress>Thivon &amp; Levadeias
11527, Goudi
Athens
Greece</sponsoraddress>
      <sponsorcountry>Greece</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study evaluates the impact of the probiotics' use on the progression of diabetes and the glycemic control of the patients, by examining parameters of the body composition, glycemic control, immunity and gut microbiota. 
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics Committee of 1st Department of Pediatrics, Athens University Medical School</ethicname>
      <ethicaddress>First Department of Pediatrics, Athens University Medical School Athens

Thivon &amp; Levadeias
11527, Goudi
Athens
Greece</ethicaddress>
      <ethicapprovaldate>26/02/2015</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>17/12/2014</ethicsubmitdate>
      <ethiccountry>Greece</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/364169-Ethics Committee.pdf</filepath>
  </attachment>
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Charikleia Stefanaki</name>
      <address>Charikleia Stefanaki, MD, MSc
34 VYZANTIOU STR
Athens, 12242
Greece</address>
      <phone>+306937036030</phone>
      <fax />
      <email>cstefanak@med.uoa.gr</email>
      <country>Greece</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Charikleia Stefanaki</name>
      <address>Charikleia Stefanaki, MD, MSc 
34 VYZANTIOU STR
Athens, 12242
Greece</address>
      <phone>+306937036030</phone>
      <fax />
      <email>cstefanak@med.uoa.gr</email>
      <country>Greece</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Charikleia Stefanaki</name>
      <address>Charikleia Stefanaki, MD, MSc
34 VYZANTIOU STR
Athens, 12242
Greece</address>
      <phone>+306937036030</phone>
      <fax />
      <email>cstefanak@med.uoa.gr</email>
      <country>Greece</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Charikleia Stefanaki</name>
      <address>Charikleia Stefanaki, MD, MSc
34 VYZANTIOU STR
Athens, 12242
Greece</address>
      <phone>+306937036030</phone>
      <fax />
      <email>cstefanak@med.uoa.gr</email>
      <country>Greece</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>